US Patent Number
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
University of Kentucky Research Foundation, Lexington, KY (US)
Ambati, Jayakrishna, "CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration" (2019). Ophthalmology and Visual Science Faculty Patents. 24.